An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression

Molecular Therapy

Volumn 4, Issue 3, 2001, Pages 223-231

  Hemminki, Akseli ^a   Belousova, Natalya ^a   Zinn, Kurt R ^b   Liu, Bin ^a   Wang, Minghui ^a   Chaudhuri, Tandra R ^b   Rogers, Buck E ^c   Buchsbaum, Donald J ^c   Siegal, Gene P ^a,d   Barnes, Mack N ^d   Gomez Navarro, Jesus ^a   Curiel, David T ^a   Alvarez, Ronald D ^d  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b University of Alabama   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus; Cancer; Gene therapy; Imaging; Ovarian cancer; Somatostatin receptor; Targeting; Thymidine kinase

Indexed keywords

ADENOVIRUS ANTIBODY; ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; BETA5 INTEGRIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; INTEGRIN; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; ASCITES; CANCER CELL; CANCER CHEMOTHERAPY; CELL DIVISION; CISTRON; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMAGING; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NONHUMAN; OVARY CANCER; PROTEIN MOTIF; PURIFICATION; VIRUS INFECTIVITY;

ADENOVIRIDAE; HERPES; SIMPLEXVIRUS;

EID: 0034857882     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0446     Document Type: Article

References (50)

1. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial
2. Adenoviral-mediated suicide gene therapy for ovarian cancer
3. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer
4. Multi-dose intraperitoneal Rad/p53 (SCH58500) gene replacement combined with chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival
5. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
6. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
7. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
8. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
9. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses
10. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
11. Update on adenovirus and its vectors
12. Report and recommendations of the panel to assess the NIH investment in research on gene therapy
13. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
14. Selectivity of TAG-72 targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro
15. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
16. Detection of coxsackie-adenovirus receptor (CAR) immunoreactivity in ovarian tumors of epithelial derivation
17. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer
18. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector
19. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy
20. Transduction efficiency of adenoviral vectors in colorectal cancer cells is determined by the presence of the coxsackie adenovirus receptor
21. Coxsackie adenovirus receptor immunohistochemical staining in superficial bladder tumors
22. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures
23. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells
24. Fiber knob modifications overcome low, heterogeneous expression of the coxsackie-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells
25. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses
26. Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle
27. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection
28. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia
29. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor Am
30. Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells
31. Clinical trials: Gene therapy death prompts review of adenovirus vector
32. Expression of α(v)β3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas
33. Expression and function of β 1 and α v β 3 integrins in ovarian cancer
34. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid
35. Inaugural article: Positron emission tomography provides molecular imaging of biological processes
36. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector
37. Simultaneous evaluation of dual gene transfer to adherent cells by γ-ray imaging
38. Detection and measurement of in vitro gene transfer by γ camera imaging
39. Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer
40. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites
41. Tumor regression in rat pancreatic (AR42J) tumor-bearing mice with Re-188 P2045-a somatostatin analog
42. Gene transfer strategies for improving radiolabeled peptide imaging and therapy
43. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
44. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir
45. Malignant ascites
46. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
47. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
48. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
49. Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells
50. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3